Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)

Launched by BEIJING TIANTAN HOSPITAL · Apr 10, 2022

Keywords

ClinConnect Summary

The LAMORA trial is a research study looking at how patients with moyamoya disease and their close family members do over the long term when they receive conservative treatment. Moyamoya disease is a condition that affects blood flow in the brain, leading to a higher risk of strokes. The study aims to understand the outcomes of patients who are treated with medications instead of surgery and to learn more about what causes the disease.

To be eligible for this study, participants must be between the ages of 2 and 60 and have a diagnosis of moyamoya disease. They should also be receiving medical treatment such as blood thinners or medications for seizures and high blood pressure. Participants will need to be able to understand the study and agree to take part, either by themselves or with help from a family member. Throughout the study, patients can expect regular follow-ups to monitor their health and gather important information about their condition. If you or someone you know may qualify, this trial could provide valuable insights into managing moyamoya disease effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with age between 2-60 years;
• • 2. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease.
• • 3. Patients are medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
• • 4. Capable of understanding the purpose and risk of the study and has signed the informed consent. If the participant is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations.
• • 5. Ability to comply with study follow-up.
• Exclusion Criteria:
• • 1. Concomitant other diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy.
• • 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement.
• • 3. Patients are allergic to the contrast agents.
• • 4. Patients are treated with direct, indirect, or combined revascularization depending on the presentation.
• • 5. Physical or subjective failure to cooperate with the examination or serious comorbid diseases.
• • 6. Patients are unable or unlikely to return for follow-up visits.
• • 7. Any other reasons that, in the opinion of the investigators, make the participant unsuitable for enrollment.